Juan Carlos Montejo

Prof. Juan Carlos Montejo

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Clinical Nutrition
Verified
Journal Article
Closed access
PSPierre Singer
Pierre Singer
ABAnnika Reintam Blaser
Annika Reintam Blaser
MBMette M. Berger
Mette M. Berger
WAWaleed Alhazzani
Waleed Alhazzani
PCPhilip Calder
Philip Calder
SBStephan C. Bischoff
Stephan C. Bischoff

14 July 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
PSPierre Singer
Pierre Singer
ABAnnika Reintam Blaser
Annika Reintam Blaser
MBMette M. Berger
Mette M. Berger
PCPhilip Calder
Philip Calder
MCMichael Casaer
Michael Casaer
SBStephan C. Bischoff
Stephan C. Bischoff

14 December 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
Jean Charles PreiserJean Charles Preiser
Jean Charles Preiser
YAYaseen M Arabi
Yaseen M Arabi
MBMette M. Berger
Mette M. Berger
MCMichael Casaer
Michael Casaer
SMStephen McClave
Stephen McClave
Paul E. WischmeyerPaul E. Wischmeyer
Paul E. Wischmeyer
The preferential use of the oral/enteral route in critically ill patients over gut rest is uniformly recommended and applied. This article provides practical guidance on enteral nutrition in compliance with recent American and European guidelines. Low-dose enteral nutrition can be safely started within 48 h after admission, even during treatment with small or moderate doses of vasopressor agents. A percutaneous access should be used when enteral nutrition is anticipated for ≥ 4 weeks. Energy delivery should not be calculated to match energy expenditure before day 4–7, and the use of energy-dense formulas can be restricted to cases of inability to tolerate full-volume isocaloric enteral nutrition or to patients who require fluid restriction. Low-dose protein (max 0.8 g/kg/day) can be provided during the early phase of critical illness, while a protein target of > 1.2 g/kg/day could be considered during the rehabilitation phase. The occurrence of refeeding syndrome should be assessed by daily measurement of plasma phosphate, and a phosphate drop of 30% should be managed by reduction of enteral feeding rate and high-dose thiamine. Vomiting and increased gastric residual volume may indicate gastric intolerance, while sudden abdominal pain, distension, gastrointestinal paralysis, or rising abdominal pressure may indicate lower gastrointestinal intolerance.

1 April 2019 in Clinical Nutrition
Verified
Journal Article
Closed access
MBMette M. Berger
Mette M. Berger
ABAnnika Reintam Blaser
Annika Reintam Blaser
PCPhilip Calder
Philip Calder
MCMichael Casaer
Michael Casaer
MHMichael Hiesmayr
Michael Hiesmayr
PSPierre Singer
Pierre Singer

9 November 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
AMAlfonso Mesejo
Alfonso Mesejo
JMJuan Carlos Montejo
Juan Carlos Montejo
CVClara Vaquerizo-Alonso
Clara Vaquerizo-Alonso
GLGabriela Lobo-Tamer
Gabriela Lobo-Tamer
MZMercedes Zabarte-Martinez
Mercedes Zabarte-Martinez
FAFátima Martínez-Lozano Aranaga
Fátima Martínez-Lozano Aranaga
Introduction: Although standard enteral nutrition is universally accepted, the use of disease-specific formulas for hyperglycemic patients is still controversial. This study examines whether a high-protein diabetes-specific formula reduces insulin needs, improves glycemic control and reduces ICU-acquired infection in critically ill, hyperglycemic patients on mechanical ventilation (MV). Methods: This was a prospective, open-label, randomized (web-based, blinded) study conducted at nine Spanish ICUs. The patient groups established according to the high-protein formula received were: group A, new-generation diabetes-specific formula; group B, standard control formula; group C, control diabetes-specific formula. Inclusion criteria were: expected enteral nutrition ≥5 days, MV, baseline glucose >126 mg/dL on admission or >200 mg/dL in the first 48 h. Exclusion criteria were: APACHE II ≤10, insulin-dependent diabetes, renal or hepatic failure, treatment with corticosteroids, immunosuppressants or lipid-lowering drugs and body mass index ≥40 kg/m2. The targeted glucose level was 110–150 mg/dL. Glycemic variability was calculated as the standard deviation, glycemic lability index and coefficient of variation. Acquired infections were recorded using published consensus criteria for critically ill patients. Data analysis was on an intention-to-treat basis. Results: Over a 2-year period, 157 patients were consecutively enrolled (A 52, B 53 and C 52). Compared with the standard control formula, the new formula gave rise to lower insulin requirement (19.1 ± 13.1 vs. 23.7 ± 40.1 IU/day, p <0.05), plasma glucose (138.6 ± 39.1 vs. 146.1 ± 49.9 mg/dL, p <0.01) and capillary blood glucose (146.1 ± 45.8 vs. 155.3 ± 63.6 mg/dL, p <0.001). Compared with the control diabetes-specific formula, only capillary glucose levels were significantly reduced (146.1 ± 45.8 vs. 150.1 ± 41.9, p <0.01). Both specific formulas reduced capillary glucose on ICU day 1 (p <0.01), glucose variability in the first week (p <0.05), and incidences of ventilator-associated tracheobronchitis (p <0.01) or pneumonia (p <0.05) compared with the standard formula. No effects of the nutrition formula were produced on hospital stay or mortality. Conclusions: In these high-risk ICU patients, both diabetes-specific formulas lowered insulin requirements, improved glycemic control and reduced the risk of acquired infections relative to the standard formula. Compared with the control-specific formula, the new-generation formula also improved capillary glycemia. Trial registration: Clinicaltrials.gov NCT1233726.

1 February 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
PSP. Singer
P. Singer
EWElisabeth De Waele
Elisabeth De Waele
CSC. Sanchez
C. Sanchez
SSS. Ruiz Santana
S. Ruiz Santana
JMJuan Carlos Montejo
Juan Carlos Montejo
IKI. Kagan
I. Kagan